Perspectives
Targeted agents: how can we improve the outcome in biliary tract cancer?
Abstract
The management of biliary tract cancer (BTC) has deeply changed in the past decade. Just few years ago patients with advanced disease had no effective treatment options but supportive therapy. Palliative chemotherapy was often administered in the absence of evidence of efficacy, as no randomized studies were available.
